Zanubrutinib’s Approval Improves Targeted Treatment for CLL - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.
Latest from Cancer Currents
01/27/2023
FDA has approved zanubrutinib (Brukinsa) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) based on results from two clinical trials. In both trials, the drug, which blocks a protein called BTK, was more effective and caused fewer side effects than other treatments.

Read the Story

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Bookmark and Share